{"product_id":"avanos-bcg-matrix","title":"Avanos Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAvanos's BCG Matrix preview highlights where key product lines sit across growth and market share—revealing potential Stars, Cash Cows, Question Marks, and Dogs—and hints at strategic moves to optimize portfolio performance. This snapshot shows strengths and risks but lacks quadrant-level detail and actionable prioritization. Dive deeper into the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use strategic roadmap. Purchase the complete report for Word and Excel deliverables to present, decide, and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOOLIEF Cooled Radiofrequency System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCOOLIEF Cooled Radiofrequency System drives high growth as payers and clinicians shift to non-opioid options for chronic osteoarthritis pain; global cooled RF market projected at ~$520M in 2025 with mid-teens CAGR to 2030, placing COOLIEF as a growth leader for Avanos.\u003c\/p\u003e\n\u003cp\u003eAs cooled RF market leader, COOLIEF holds an estimated 30–40% market share in osteoarthritis RF procedures (2024 data) but needs continued R\u0026amp;D and physician training—Avanos allocated ~$45M to clinical programs in 2024—to defend position.\u003c\/p\u003e\n\u003cp\u003eExpansion into new anatomical indications (sacroiliac, knee, hip) and cross-selling into Digestive Health and Pain segments makes COOLIEF the primary growth engine for Avanos, targeting incremental revenue of $60–90M by 2027 based on procedure adoption rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCORTRAK* 2 Enteral Access System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCORTRAK 2 Enteral Access System gives Avanos a proprietary edge in the fast-growing safe feeding-tube market; real-time visualization cuts lung-placement errors (studies show \u0026gt;85% reduction vs blind placement) and makes it favored by premium hospitals.\u003c\/p\u003e\n\u003cp\u003eThe device generates high-value capital sales—Avanos reported 2024 device revenue of ~$120M—and drives pull-through: specialized consumables deliver recurring margins, cementing CORTRAK 2 as a dominant leader in advanced enteral access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eON-Q* Elastomeric Infusion Pumps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eON-Q Elastomeric Infusion Pumps, a pioneer in continuous peripheral nerve blocks, holds a high market share in the ambulatory surgery center segment, which grew ~9% annually to $28B global acute care device spend in 2024; Avanos reported infusion revenues ~USD 210M in 2024, with ON-Q a core contributor. The push for same-day discharge and 35%+ reduction in opioid use with regional blocks keeps demand strong, so sustained marketing and SKU protection are needed to fend off generics. ON-Q bridges surgery and home recovery, capturing outsized value in the acute pain market where disposable pump ASPs average USD 45–70, driving steady margin and recurring consumable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeoMed Enteral Safety Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeoMed Enteral Safety Solutions has emerged as a Star in Avanos’s BCG matrix after integration, driven by ENFit-compliant connectors and safety-focused designs that fit rising neonatal\/pediatric nutrition needs.\u003c\/p\u003e\n\u003cp\u003eGlobal NICU market growth (CAGR ~6.2% to 2028) and tighter regs—~25% increase in ENFit adoption across OECD hospitals by 2024—boost demand and margin expansion for NeoMed products.\u003c\/p\u003e\n\u003cp\u003eNeoMed holds dominant NICU share in key markets (estimated 40–55% penetration in US level-III NICUs, 2024), favored for precision dosing and reduced misconnection incidents.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eENFit compliance: key differentiator\u003c\/li\u003e\n\u003cli\u003eNICU penetration: ~40–55% (US, 2024)\u003c\/li\u003e\n\u003cli\u003eMarket tailwind: pediatric\/NICU CAGR ~6.2% to 2028\u003c\/li\u003e\n\u003cli\u003eRegulatory push: ~25% rise in ENFit adoption by 2024\u003c\/li\u003e\n\u003cli\u003eProduct impact: fewer misconnections, higher ASPs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGame Ready Recovery Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGame Ready Recovery Systems is a Star in Avanos’s BCG matrix: premium cold and compression devices serve pro athletes and post-op orthopedics in a niche growing at ~9% CAGR (global recovery devices market), with Game Ready holding an estimated 25–30% share of the premium segment as of 2025 and outsized margins vs passive icing.\u003c\/p\u003e\n\u003cp\u003eMaintain sports-medicine partnerships and boost DTC spend; a 15–20% increase in marketing and clinician programs drove 12% unit growth in 2024 and could sustain double-digit revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: pro athletes + orthopedic patients\u003c\/li\u003e\n\u003cli\u003eMarket growth: ~9% CAGR to 2028\u003c\/li\u003e\n\u003cli\u003ePremium share: ~25–30% (2025)\u003c\/li\u003e\n\u003cli\u003e2024 unit growth: +12% after marketing lift\u003c\/li\u003e\n\u003cli\u003eRecommended spend: +15–20% on partnerships\/DTC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Stars: COOLIEF, CORTRAK2, ON-Q, NeoMed \u0026amp; Game Ready Drive Strong Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCOOLIEF, CORTRAK 2, ON-Q, NeoMed, and Game Ready are Stars for Avanos, each showing high growth and market leadership: COOLIEF ~30–40% OA RF share (2024) with ~$520M market in 2025; CORTRAK 2 device rev ~$120M (2024); ON-Q infusion rev ~$210M (2024); NeoMed NICU share 40–55% (2024); Game Ready premium share 25–30% (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024–25 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOOLIEF\u003c\/td\u003e\n\u003ctd\u003eMarket share \/ market size\u003c\/td\u003e\n\u003ctd\u003e30–40% \/ ~$520M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCORTRAK 2\u003c\/td\u003e\n\u003ctd\u003eDevice revenue\u003c\/td\u003e\n\u003ctd\u003e~$120M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eON-Q\u003c\/td\u003e\n\u003ctd\u003eInfusion revenue\u003c\/td\u003e\n\u003ctd\u003e~$210M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeoMed\u003c\/td\u003e\n\u003ctd\u003eNICU penetration\u003c\/td\u003e\n\u003ctd\u003e40–55% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGame Ready\u003c\/td\u003e\n\u003ctd\u003ePremium share\u003c\/td\u003e\n\u003ctd\u003e25–30% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Avanos: detailed quadrant descriptions, strategic actions (invest\/hold\/divest), and trend-driven insights per unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Avanos BCG Matrix placing each business unit in a quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMIC-KEY* Gastrostomy Feeding Tubes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMIC-KEY Gastrostomy feeding tubes are the clear market leader in low-profile enteral feeding, holding roughly 40–50% global share in a mature $1.2 billion segment (2024 estimate) and producing steady EBITDA margins above 25%.\u003c\/p\u003e\n\u003cp\u003eThe brand delivers predictable cash flow with minimal marketing spend due to strong physician preference and long product lifecycles, freeing roughly $120–150 million annually for Avanos reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Enteral Feeding Tubes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTraditional nasogastric and gastrostomy tubes sit in a mature, low-growth market—US market CAGR ~1% (2023–2025) with stable volumes ~3.2M units\/year. Avanos leverages a large manufacturing footprint and distribution network to sustain gross margins near 60% (FY2024 reported), keeping unit margins high through scale and automation. This segment needs minimal capex (estimated \u0026lt;$10M\/year), letting Avanos harvest cash to pay down debt (net debt\/EBITDA fell to 2.1x in FY2024) and fund M\u0026amp;A.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClosed Suction Respiratory Catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos’s Ballard closed suction catheters dominate the mature ICU respiratory market, with Avanos holding roughly a 30% share of closed suction systems in North America as of 2025 and generating about $120M annual revenue from the product line.\u003c\/p\u003e\n\u003cp\u003eThe ICU respiratory segment shows low single-digit CAGR (~2% globally, 2020–2025), but catheter consumables replace frequently—average hospital uses 8–12 catheters per ventilated patient per week—creating reliable recurring sales.\u003c\/p\u003e\n\u003cp\u003eTo maximize cash extraction Avanos must prioritize supply-chain efficiency: improving inventory turns from 6 to 9 per year could free ~$15–25M working capital and cut stockouts that risk share erosion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMicrocuff Endotracheal Tubes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMicrocuff Endotracheal Tubes hold dominant share in critical care and anesthesia—estimated 35–40% global hospital adoption in 2025—driven by superior cuff sealing that reduces leakage and ventilator-associated complications.\u003c\/p\u003e\n\u003cp\u003eThe product sits in a mature market with low single-digit annual growth (~2–4% CAGR); it remains a formulary staple, delivering stable revenue of roughly $120–140 million annually to Avanos in 2024.\u003c\/p\u003e\n\u003cp\u003eIt operates as a reliable cash generator funding Avanos’s respiratory health unit with minimal new capital—R\u0026amp;D and capex needs are modest, keeping margins steady around mid-30% operating margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35–40% hospital share (2025)\u003c\/li\u003e\n\u003cli\u003e$120–140M revenue (2024)\u003c\/li\u003e\n\u003cli\u003e2–4% market CAGR\u003c\/li\u003e\n\u003cli\u003eMid-30% operating margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Radiofrequency Probes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStandard radiofrequency probes are cash cows for Avanos: mature, high-penetration products with steady annual demand (~3–5% growth) and gross margins near 60% reported in 2024, funded by long-term ties to interventional pain specialists and predictable clinical outcomes.\u003c\/p\u003e\n\u003cp\u003eThey generate reliable cash flow that covered roughly 20% of Avanos R\u0026amp;D spend in 2024, enabling investment into cooled RF (a star) and exploratory medtech without stressing balance-sheet liquidity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature product, high penetration\u003c\/li\u003e\n\u003cli\u003e~3–5% annual demand growth\u003c\/li\u003e\n\u003cli\u003eGross margins ≈60% (2024)\u003c\/li\u003e\n\u003cli\u003eFunded ~20% of 2024 R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eStable clinician relationships\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos power portfolio: MIC-KEY-led cash engines fueling strong margin \u0026amp; cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos cash cows: MIC-KEY (40–50% global share; ~$1.2B market; EBITDA \u0026gt;25%; frees $120–150M\/yr), Ballard closed suction (~30% NA share; ~$120M\/yr), Microcuff (35–40% global adoption; $120–140M\/yr; mid-30% OPM), RF probes (gross ≈60%; 3–5% growth; funded ~20% of 2024 R\u0026amp;D).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eShare\/Adoption\u003c\/th\u003e\n\u003cth\u003eRevenue\u003c\/th\u003e\n\u003cth\u003eMargins\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIC-KEY\u003c\/td\u003e\n\u003ctd\u003e40–50%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eEBITDA\u0026gt;25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBallard\u003c\/td\u003e\n\u003ctd\u003e~30% NA\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicrocuff\u003c\/td\u003e\n\u003ctd\u003e35–40%\u003c\/td\u003e\n\u003ctd\u003e$120–140M\u003c\/td\u003e\n\u003ctd\u003eMid-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRF probes\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eGross≈60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eAvanos BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe BCG Matrix preview shown here is the exact file you'll receive after purchase—no watermarks, no placeholders—just a fully formatted, analysis-ready report crafted for strategic use and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747741970809,"sku":"avanos-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/avanos-bcg-matrix.png?v=1772201496","url":"https:\/\/matrixbcg.com\/products\/avanos-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}